IFF · 10-Q · 2026Q2 · Full report
Portfolio Reshaping (M&A / Divestiture)
INTERNATIONAL FLAVORS & FRAGRANCES INC · 2026-08-04 · Importance 71 · Surprise 60 · In source text
On May 29, 2026, IFF entered into a definitive agreement to divest its Food Ingredients disposal group and classified that group, together with the SCL disposal group, as discontinued operations during the second quarter. The Food Ingredients business includes natural, artificial and plant-based specialty food ingredients, specialty soy protein, emulsifiers and sweeteners. Management expects the transaction to support portfolio optimization and states that the remaining $2.0 billion of its enhanced repurchase authorization will be executed following closing of the Food Ingredients divestiture, with program completion expected by the end of 2027.
Key facts
- Comparable portfolio results for the first six months exclude the impact of divestitures which was approximately $379 million. source
- Comparable portfolio results exclude divestiture impacts of approximately $107 million from the sale of the Pharma Solutions disposal group, the Nitrocellulose disposal group and Rene Laurent business in France. source
- Impairment of goodwill of $34 million in the 2025 period represents the impairment of goodwill attributable to the portion of the Food Ingredients reporting unit that is not included within the Food Ingredients or SCL disposal groups. source
- Comparable portfolio results exclude the impact of the divestiture of the Rene Laurent business with a sales impact of approximately $4 million. source
- On May 1, 2025 and May 9, 2025 the Company completed the divestitures of the Pharma Solutions disposal group and the Nitrocellulose business, respectively, and accordingly there were no Pharma Solutions segment results reported for Q2 2026. source
- The Company is organized into three reportable operating segments: Taste, Health & Biosciences, and Scent. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | -19.4% | Comparable portfolio results for the first six months exclude the impact of divestitures which was approximately $379 million. |
| revenue | negative | realized | -5.5% | Comparable portfolio results exclude divestiture impacts of approximately $107 million from the sale of the Pharma Solutions disposal… |